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Background and Purpose: Pancreatic islet transplantation is a promising therapeutic
approach for Type 1 diabetes. A major prerequisite for the survival of grafted islets is
a rapid revascularization after transplantation. Erythropoietin (EPO), the primary reg-
ulator of erythropoiesis, has been shown to promote angiogenesis. Therefore, we
investigated in this study whether EPO improves the revascularization of
transplanted islets.
Experimental Approach: Islets from FVB/N mice were transplanted into dorsal
skinfold chambers of recipient animals, which were daily treated with an intraperito-
neal injection of EPO (500 IUkg−1) or vehicle (control) throughout an observation
period of 14 days. In a second set of experiments, animals were only pretreated with
EPO over a 6-day period prior to islet transplantation. The revascularization of the
grafts was assessed by repetitive intravital fluorescence microscopy and immunohis-
tochemistry. In addition, a streptozotocin-induced diabetic mouse model was used to
study the effect of EPO-pretreatment on the endocrine function of the grafts.
Key Results: EPO treatment slightly accelerated the revascularization of the islet
grafts. This effect was markedly more pronounced in EPO-pretreated animals,
resulting in significantly higher numbers of engrafted islets and an improved perfu-
sion of endocrine tissue without affecting systemic haematocrit levels when com-
pared with controls. Moreover, EPO-pretreatment significantly accelerated the
recovery of normoglycaemia in diabetic mice after islet transplantation.
Conclusion and Implications: These findings demonstrate that, particularly, short-
term EPO-pretreatment represents a promising therapeutic approach to improve the
outcome of islet transplantation, without an increased risk of thromboembolic
events.
Abbreviations: ang-2, angiopoietin-2; EPO, erythropoietin; FITC, fluorescein isothiocyanate; pre, pretreatment; RBC, red blood cell; STZ, streptozotocin; TIE2, angiopoietin-1 receptor; Tx,
transplantation.
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1 | INTRODUCTION
Islet transplantation is a promising strategy for the curative treatment
of Type 1 diabetes mellitus (McCall & Shapiro, 2012). In comparison
to whole organ pancreas transplantation, the minimally invasive trans-
plantation of Langerhans islets reduces the operative trauma and also
the risk of complications induced by exocrine pancreatic tissue. How-
ever, only 50–70% of patients remain insulin-independent at 5 years
after transplantation (Shapiro, Pokrywczynska, & Ricordi, 2017). This
can be explained by the fact that the procedure is still hampered by
the inefficiency of the islet isolation process and a low rate of suc-
cessfully engrafted islets (Ahearn, Parekh, & Posselt, 2015). The latter
is caused by an insufficient graft revascularization during the initial
post-transplantation period, leading to apoptotic and necrotic cell
death (Davalli et al., 1996; Schramm, Yamauchi, Vollmar, Vajkoczy, &
Menger, 2003). Therefore, it is of great clinical interest to identify
novel compounds, which are capable of accelerating the revasculariza-
tion of transplanted islets.
The glycoprotein erythropoietin (EPO) is produced by the kidney
and regulates the formation of red blood cells (RBCs) during
haematopoiesis (Jelkmann, 1992). EPO binds to its corresponding
receptor EPO receptor, which is mainly expressed on erythroid cells.
Beside the function of EPO on haematopoiesis, several studies also
reported a pro-angiogenic activity of this glycoprotein. In fact, EPO
receptors are also expressed on endothelial cells and the binding of
EPO leads to a signal transduction triggering the expression of pro-
angiogenic genes, such as those for VEGF, angiopoietin-1 receptor
(TIE)-2, and angiopoietin (ang)-2 (Alvarez Arroyo et al., 1998; Li, Lu,
Keogh, Yu, & Wei, 2007). This stimulates endothelial cell proliferation
and, thus, supports the formation of new blood vessels (Karschnia
et al., 2018; Watanabe et al., 2005). EPO has also been shown to pro-
tect against hypoxia-induced apoptosis (Grimm et al., 2002; Harder
et al., 2009; Heikal et al., 2016). Moreover, EPO increases the expres-
sion of endothelial NOS, resulting in elevated NO levels (Burger et al.,
2006). This in turn leads to the generation of cGMP, which induces
smooth muscle relaxation in blood vessels, resulting in an improved
tissue perfusion (Katsuki & Murad, 1977).
Interestingly, Fenjves et al. (2003) reported that pancreatic islets
express EPO receptors and the cultivation of islets with EPO protects
them from cytokine-induced apoptosis. In addition, EPO reduces pan-
creatic β-cell damage by promoting anti-oxidative processes (Chen
et al., 2015; Choi et al., 2010), and EPO also decreases blood glucose
levels in diabetic mouse models (Katz et al., 2010).
Based on these findings, we hypothesized that EPO would accel-
erate the revascularization and improve the engraftment of freely
transplanted pancreatic islets. To test this, islets were isolated from
GFP-positive FVB/N donor mice and transplanted into dorsal skinfold
chambers of wild-type animals, which were treated or pretreated with
EPO or vehicle. The cellular composition, the process of revasculariza-
tion, and the take rate of the grafts were analysed by means of repeti-
tive intravital fluorescence microscopy and immunohistochemistry.
Finally, we assessed the effect of the glycoprotein on the endocrine
function of transplanted islets in a diabetic mouse model.
2 | METHODS
2.1 | Animals
All animal care and experimental procedures complied with the Ger-
man legislation on protection of animals and the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory Animals (Insti-
tute of Laboratory Animal Resources, National Research Council,
Washington DC, USA), and were approved by the local governmental
animal protection committee (permission number: 58/2015). Animal
studies are reported in compliance with the ARRIVE guidelines (Kil-
kenny et al., 2010) and with the recommendations made by the British
Journal of Pharmacology.
For the dorsal skinfold chamber model, 12- to 24-week-old trans-
genic FVB/N-TgN (Tie2/GFP) 287 Sato mice (Institute for Clinical and
Experimental Surgery, Homburg/Saar, Germany) with a body weight
of 25–30 g were used as donors for islet isolation. These mice express
the reporter gene GFP under the transcriptional control of the endo-
thelial TIE2 promotor (Motoike et al., 2000). Eight- to 10-week-old
FVB/N wild-type mice with a body weight of 22–27 g served as recip-
ients for islet transplantation. For the kidney capsule model, we used
12- to 24-week-old C57BL/6J mice (Institute for Clinical and Experi-
mental Surgery, Homburg/Saar, Germany) with a body weight of 25–
30 g as donors for islet isolation. Eight-week-old male C57BL/6J mice
with a body weight of 25–26 g served as recipients. All mice were
housed one per cage under a 12/12-hr day/night cycle and had free
access to water and standard pellet chow (Altromin, Lage, Germany).
At the end of experiments, the animals were killed by cervical
dislocation.
What is already known
• The rapid revascularization of isolated pancreatic islets is
crucial for their successful transplantation.
• Erythropoietin exerts pro-angiogenic properties in vitro
and in vivo.
What this study adds
• Pretreatment with erythropoietin accelerates the revas-
cularization of transplanted pancreatic islets in FVB/N
mice.
• Pretreatment with erythropoietin accelerates the restora-
tion of normoglycaemia in mice with streptozotocin-
induced diabetes.
What is the clinical significance
• Pretreatment with erythropoietin represents a promising
pharmacological approach to improve the outcome of
islet transplantation.
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2.2 | Isolation of pancreatic islets
Mice were anaesthetized by i.p. injection of ketamine (75 mgkg−1
body weight) and xylazine (25 mgkg−1 body weight). Following mid-
line laparotomy, the pancreatic duct was injected with 1 mgml−1 of
collagenase NB 4G containing 25 μlml−1 of neutral red solution, and
pancreatic islets were isolated as described previously in detail (Beger,
Cirulli, Vajkoczy, Halban, & Menger, 1998).
2.3 | Dorsal skinfold chamber
To analyse the revascularization of transplanted islets in vivo, we used
the dorsal skinfold chamber model. This represents a suitable model
to study non-invasively the microcirculatory parameters of striated
muscle and s.c. tissue throughout an observation period of 2 weeks
(Laschke & Menger, 2016). Moreover, we and others have shown that
the dorsal skinfold chamber model can be used to investigate angio-
genic processes of transplanted islets (Menger, Vajkoczy, Beger, &
Messmer, 1994; Nalbach et al., 2019; Nishimura et al., 2013). The
chamber was prepared and implanted as described previously in detail
(Laschke, Vollmar, & Menger, 2011). Briefly, mice were anaesthetized
as above, and two symmetrical titanium frames were implanted on
the extended dorsal skinfold of the animals. Skin, subcutis, and the
retractor muscle were completely removed in a circular area of
15 mm. The remaining layers, consisting of striated muscle, subcutis,
and cutis, were covered by a removable cover glass, providing direct
microscopic access to the microcirculation of the chamber. After the
procedure, the animals were allowed to recover for a 72-hr period.
For the transplantation of pancreatic islets, mice were
anaesthetized, the cover glass was removed, and the chamber was
washed twice with saline. Then, six to eight freshly isolated islets were
transplanted onto the striated muscle tissue. After transplantation,
the chamber was sealed again with a new cover glass.
2.4 | Intravital fluorescence microscopy
The anaesthetized mice were fixed on a plexiglas stage and received a
retrobulbary i.v. injection of 0.05-ml 5% fluorescein isothiocyanate
(FITC)-dextran for contrast enhancement by staining of blood plasma.
Moreover, 0.05-ml 2% rhodamine 6G, which accumulates in endo-
crine but not in striated muscle tissue by extravasation from fenes-
trated endothelium, was given i.v. for the visualization of endocrine
revascularization (Vajkoczy, Menger, Simpson, & Messmer, 1995).
Then, the dorsal skinfold chamber was positioned under a Zeiss micro-
scope (Zeiss, Oberkochen, Germany) with a 100-W mercury lamp
attached to a blue (excitation wavelength: 450–490 nm/emission
wavelength: >515 nm) and a green (530–560 nm/>585 nm) filter
block. The microscopic images were recorded by a charge-coupled
device video camera (FK6990; Pieper, Schwerte, Germany) and trans-
ferred to a monitor (Trinitron; Sony, Tokyo, Japan) and a DVD system
(DVD-HR775; Samsung, Eschborn, Germany) for offline evaluation.
Quantitative analysis of the microscopic images was performed
by the computer-assisted image analysis system CapImage (Zeintl,
Heidelberg, Germany) and included the determination of the graft ini-
tial size (mm2), revascularized area (mm2), functional capillary density
(cmcm−2), and endocrine revascularization, as previously described
(Ampofo et al., 2015; Menger, Vajkoczy, Leiderer, Jager, & Messmer,
1992). We further measured microhaemodynamic parameters, such as
diameter (μm), centreline RBC velocity (μms−1), and volumetric blood
flow (pls−1), of individual microvessels within the grafts (Ampofo
et al., 2015; Menger et al., 1992). Moreover, we assessed the take
rate (%), that is, the fraction of engrafted islets in relation to the num-
ber of transplanted islets on Day 14. Finally, we investigated the
diameter of first-, second-, and third-order arterioles and venules of
the chamber tissue to analyse EPO-induced vasodilatation.
2.5 | Diabetic mouse model
C57BL/6J mice were anaesthetized, and the kidney was exposed by
an incision of the right flank. A small nick was made in the kidney cap-
sule with the bevel of a 10-μl Hamilton syringe over the inferior renal
pole. The islets were then deposited under the capsule through the
nick towards the superior pole of the kidney. The kidney was returned
to the abdomen, and the incisions in the abdominal wall and the skin
were closed. After the procedure, the mice received a s.c. injection of
carprofen (5 mgkg−1 body weight). Blood glucose levels were moni-
tored at the indicated time points by a blood glucose monitoring sys-
tem (Beurer Medical, Germany). Hyperglycaemia was defined by
blood glucose >12.5 mmoll−1.
2.6 | Experimental protocol
Dorsal skinfold chamber model: Pancreatic islets were isolated from
10 GFP-positive FVB/N donor mice. A total number of 32 FVB/N
wild-type mice were equipped with dorsal skinfold chambers. The
mice were assigned to four randomized experimental groups of eight
animals each. In a first set of experiments, EPO (500 IUkg−1 body
weight, i.p.) or vehicle (ctrl; 100-μl saline, i.p.) was given daily, starting
from the day of islet transplantation (Day 0) until the end of the
observation period (Day 14). In a second set of experiments, the ani-
mals were pretreated daily with the identical dose of EPO (500 IUkg−1
body weight, i.p.; EPO-pre) or vehicle (100-μl saline, i.p.; ctrl-pre) over
6 days prior to the islet transplantation. Repetitive intravital fluores-
cence microscopy was performed on Days 0, 3, 6, 10, and 14 after
islet transplantation. At the end of the experiments, blood samples
were drawn from the vena cava, and the haematocrit was determined
by a haematology analyser (Abaxis VetScan HM5; scil animal care
company GmbH, Viernheim, Germany). Subsequently, the islet-con-
taining chamber tissue was excised for further immunohistochemical
analyses. Moreover, three additional vehicle- and EPO-pretreated
mice were already killed on Day 6 after islet transplantation for immu-
nohistochemical analyses of early engrafted islets. The animal
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experiments and the histological analysis were performed under
blinded conditions.
Diabetic mouse model: Seven days before transplantation, a dia-
betic phenotype was induced in recipient mice by an injection of
150 mgkg−1 i.p. streptozotocin (STZ) in citrate buffer, pH 6.4. In
addition, mice were pretreated with EPO (500 IUkg−1 body weight,
i.p.; EPO-pre) or vehicle (100 μl saline, i.p.; ctrl-pre) over 6 days
before transplantation. Blood glucose levels were measured before
STZ application as well as 4 days after the STZ injection. Mice with
a blood glucose level > 12.5 mmoll−1 and a body weight of 24–26 g
were used as recipients for islet transplantation. Seven days after
STZ application, a suboptimal number of islets (300) that did not
restore normoglycaemia within 10 days was transplanted. After
28 days, the kidneys were excised for immunohistochemical
analyses.
2.7 | Plasma insulin content
The insulin content of plasma samples was quantified by means of an
ELISA kit from Thermo Fisher Scientific (Braunschweig, Germany),
according to the manufacturer's instructions.
2.8 | Immunohistochemistry
For the preparation of histological sections, specimens of islet-con-
taining dorsal skinfold chamber or kidney capsule preparations were
fixed for 24 hr in 4% formalin. In addition, freshly isolated islets
were incubated for 45 min at 37C in 100-μl HepatoQuick®, 50-μl
human citrate plasma, and 10-μl 10% CaCl2 solution. The resulting
clot was also fixed for 24 hr in 4% formalin. The formalin-fixed
specimens were then embedded in paraffin, and 3-μm-thick sec-
tions were cut.
The antibody-based procedures used in this study comply with
the recommendations made by the British Journal of Pharmacology
(Alexander et al., 2018). The sections were stained with anti-insulin,
anti-glucagon, anti-somatostatin, anti-CD31 and anti-GFP anti-
bodies, which were detected by corresponding fluorescence-
coupled secondary antibodies. Cell nuclei were stained with
Hoechst 33342. The sections were analysed by means of fluores-
cence microscopy (BX60F; Olympus, Hamburg, Germany). The num-
bers of insulin-, glucagon-, somatostatin-, and CD31-positive cells
were counted using ImageJ software (ImageJ, RRID:SCR_003070)
and given in % of all islet cells. In addition, the numbers of GFP/
CD31-positive cells were counted and given in % of all CD31-posi-
tive cells.
2.9 | Data and statistical analysis
We decided sample size for animal studies based on a survey of data
from published studies. The number of mice was not predetermined
by a statistical method, and no mice were excluded from statistical
analysis. The data and statistical analysis comply with the recommen-
dations of the British Journal of Pharmacology on experimental design
and analysis in pharmacology (Curtis et al., 2015). After testing the
data for normal distribution and equal variance, differences between
two groups were assessed by the unpaired Student's t test. To test for
time effects within individual groups, one-way ANOVA for repeated
measures was applied. This was followed by the Student–Newman–
Keuls post hoc test, including the correction of the α-error according
to Bonferroni probabilities to compensate for multiple comparisons
(SigmaPlot, RRID:SCR_003210). All values are expressed as
mean ± SEM. Statistical significance was accepted for P < .05. The
declared group size is the number of independent values, and the sta-
tistical analysis was done using these independent values.
2.10 | Materials
Collagenase NB 4G was purchased from SERVA Elektrophoresis
GmbH (Heidelberg, Germany). Neutral red solution, FITC-dextran
150,000, rhodamine 6G, Hoechst 33342, STZ and avidin-peroxidase
were purchased from Sigma-Aldrich (Taufkirchen, Germany).
Mayer's hemalaun solution was received from Merck (Darmstadt,
Germany), ketamine (Ursotamin®) from Serumwerke Bernburg
(Bernburg, Germany) and xylazine (Rompun®) from Bayer (Leverku-
sen, Germany). HepatoQuick® and EPO-β (recombinant human
EPO, NeoRecormon®) were purchased from Roche (Basel, Switzer-
land). The antibody anti-CD31 (Dianova Cat# DIA-310, RRID:
AB_2631039) was received from Dianova (Germany), the antibody
anti-GFP from Rockland Immunochemical Inc. (Limerick, USA) and
the antibodies anti-insulin, anti-glucagon and anti-somatostatin as
well as 3-amino-9-ethylcarbazole (AEC Substrate System) from
Abcam (Cambridge, UK).
2.11 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in
the Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al.,
2019).
3 | RESULTS
3.1 | Characteristics of isolated islets before and
after transplantation
Islets were isolated and stained for the detection of insulin-,
glucagon-, somatostatin-, and CD31-positive cells (Figure 1a–d). The
quantitative analysis of these stains revealed that ~70% of the cells
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within isolated islets were positive for insulin, whereas ~10%
expressed glucagon, ~5% somatostatin, and ~10% the endothelial
marker CD31 (Figure 1e).
The effect of EPO on the revascularization of transplanted islets
was investigated in the mouse dorsal skinfold chamber model. For this
purpose, the recipient animals were either treated with EPO or vehi-
cle, starting from the day of islet transplantation until the end of the
observation period, or pretreated over 6 days prior to islet transplan-
tation (Figure 1f). Using intravital fluorescence microscopy, the posi-
tion of the grafts within the host tissue of the chamber could easily be
F IGURE 1 Characteristics of isolated islets before and after transplantation. (a) Bright field microscopy of neutral red-stained isolated islets
from GFP+/Tie+ FVB/N donor mice. Scale bar: 200 μm. (b–d) Immunofluorescence staining of insulin/glucagon (b), insulin/somatostatin (c), and
insulin/CD31 (d) within isolated islets. Cell nuclei were stained with Hoechst 33342 (blue). Scale bar: 25 μm. (e) Insulin-, glucagon-, somatostatin-,
and CD31-positive cells (in % of all islet cells) within isolated islets (n = 10). Mean ± SEM. (f) Schematic illustration of the experimental setting of
EPO administration and islet transplantation. In a first set of experiments, EPO or vehicle was administered daily, starting from the day of islet
transplantation (Tx, Day 0) until the end of the observation period (Day 14). In a second set of experiments, the animals were only pretreated
daily with EPO or vehicle over 6 days prior to islet transplantation (EPO-pre). Intravital fluorescence microscopy was performed on Days 0, 3,
6, 10, and 14 after islet transplantation. (g) Observation window of a dorsal skinfold chamber containing eight transplanted neutral red-stained
islets on Day 0. Scale bar: 1 mm. (h,i) Intravital fluorescence microscopic images of a neutral red-stained islet within the dorsal skinfold chamber
of a vehicle-treated animal on Day 0. The plasma marker FITC-dextran was used for the visualization of blood-perfused microvessels surrounding
the islet (marked by dotted line) in blue light epi-illumination (h). The islet was detected by neutral red-fluorescence in green light epi-illumination
(i). Scale bar: 50 μm
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determined by their strong neutral red-staining on Day 0 (Figure 1g–
i). Of note, the initial size of the transplanted islets did not markedly
differ between the experimental groups (EPO: 0.08 ± 0.01 mm2
vs. ctrl: 0.11 ± 0.02 mm2 and EPO-pre: 0.10 ± 0.01 mm2 vs. ctrl-pre:
0.10 ± 0.02 mm2).
3.2 | Effect of EPO treatment on the
revascularization of transplanted islets
In the first set of experiments, we examined the efficiency of EPO
treatment in accelerating the revascularization of transplanted islets.
F IGURE 2 Effect of EPO treatment on the revascularization of transplanted islets. (a) Intravital microscopic images of islets (marked by
dotted lines) on Days 6 and 14 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were treated with vehicle (ctrl) or
EPO. The plasma marker FITC-dextran was used for the visualization of microvessels in blue light epi-illumination. Scale bar: 50 μm. (b,c)
Functional capillary density (cmcm−2) (b) and revascularized area (mm2) (c) of islets on Days 0, 3, 6, 10, and 14 after transplantation into the
dorsal skinfold chamber of FVB/N mice, which were treated with vehicle (ctrl, n = 8) or EPO (n = 8). Mean ± SEM. #P < .05, significantly different
from Day 0 in each individual group; †P < .05, significantly different from Days 0 and 3 in each individual group; ‡P < .05, significantly different
from Days 0, 3, and 6 in each individual group; *P < .05, significantly different from ctrl. (d) Intravital microscopic images of islets as described in
(a). Rhodamine 6G was used to visualize endocrine revascularization in green light epi-illumination. Scale bar: 50 μm. (e) Endocrine
revascularization of islets on Days 0, 3, 6, 10, and 14 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were treated
with vehicle (ctrl, n = 8) or EPO (n = 8). Mean ± SEM. † P < .05, significantly different from Days 0 and 3 in each individual group. (f,g) Take rate
(%) (f) and systemic haematocrit (%) (g) on Day 14 after islet transplantation into the dorsal skinfold chamber of FVB/N mice, which were treated
with vehicle (ctrl, n = 8) or EPO (n = 8). Mean ± SEM. *P < .05, significantly different from vehicle
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We found that the functional capillary density and revascularized area
of the grafts progressively increased in vehicle- and EPO-treated ani-
mals (Figure 2a–c). EPO slightly accelerated the revascularization pro-
cess, as shown by a significantly higher functional capillary density on
Day 6 when compared to controls (Figure 2a,b). The diameters of the
microvessels within the islets of both the vehicle- and the EPO-
treated animals decreased over time, which is a typical sign for blood
vessel stabilization and maturation (Diez et al., 2017). The centreline
RBC velocity and volumetric blood flow increased throughout the
observation period of 14 days without significant differences between
the groups (Table 1).
Next, we assessed the effect of EPO treatment on the islets'
endocrine revascularization; that is, the ratio between the size of the
microvascularly perfused endocrine tissue and the original islet size
after transplantation (Figure 2d,e). EPO treatment increased the endo-
crine revascularization of the islets, but without a significant differ-
ence compared with controls (Figure 2e). Moreover, EPO treatment
did not improve the take rate of the grafts, which was ~85% in both
groups (Figure 2f). Finally, we found that the daily administration of
EPO over 14 days did significant raise the systemic haematocrit levels
of the animals (Figure 2g).
3.3 | Effect of EPO-pretreatment on the
revascularization of transplanted islets
In the second set of experiments, mice were only pretreated with
EPO over 6 days prior to islet transplantation. Of interest, this short-
term pretreatment was much more effective when compared to the
administration of EPO during the first 14 days after transplantation.
We detected a significantly higher functional capillary density during
the first 10 days after transplantation and a markedly larger
revascularized islet area in EPO-pretreated mice when compared with
controls (Figure 3a–c). Consistent with these findings, EPO also signif-
icantly improved the endocrine revascularization of the grafts during
the entire observation period (Figure 3d,e). The additional analysis of
microhaemodynamic parameters revealed an accelerated decrease of
the diameter as well as an increase of the centreline RBC velocity and
the volumetric blood flow of microvessels within transplanted islets of
EPO-pretreated animals (Table 2). Furthermore, the number of suc-
cessfully engrafted islets was significantly elevated in EPO-pretreated
animals when compared with controls, as indicated by a take rate of
almost 100% (Figure 3f). In contrast to EPO treatment (Figure 2g), the
6-day administration of the glycoprotein prior to islet transplantation
did not elevate the systemic haematocrit levels of the animals at the
end of the 14-day observation period (Figure 3g).
3.4 | Effect of EPO on vasodilatation
We further determined the diameter of microvessels within the dorsal
skinfold chamber of EPO-treated and EPO-pretreated animals. Our
analyses revealed that EPO-pretreatment significantly increases the
diameter of arterioles and venules during the first 6 days after islet
transplantation when compared to vehicle-pretreated controls (Fig-
ure 4a–d). Of note, this vasodilator effect of the glycoprotein occurred
in EPO-treated animals only 6 days after islet transplantation (Fig-
ure 4e,f).
3.5 | Immunohistochemical analysis of
transplanted islets
Because the revascularization of grafted islets was much improved in
EPO-pretreated mice, compared with EPO-treated animals, we only
analysed the islet grafts of the pretreated mice in more detail by
immunohistochemistry. These analyses confirmed our intravital fluo-
rescent microscopic findings. On Day 6 after transplantation, islets in
EPO-pretreated mice exhibited a significantly higher fraction of
CD31-positive endothelial cells, compared with controls (Figure 5a,b),
indicating an improved revascularization at this early time point. As
expected, this difference was not present on Day 14 after islet
TABLE 1 Diameter (μm), centreline RBC velocity (μms−1), and volumetric blood flow (pls−1) of newly formed microvessels within islets on
Days 3, 6, 10, and 14 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were treated with vehicle (ctrl, n = 8) or EPO
(n = 8)
D3 D6 D10 D14
Diameter (μm)
ctrl 11.8 ± 1.8 12.1 ± 0.8 9.4 ± 0.5# 9.1 ± 0.2#
EPO 12.4 ± 0.7 10.7 ± 0.6* 9.6 ± 0.4* 9.5 ± 0.5*
Centreline RBC velocity (μms−1)
ctrl 51.9 ± 31.7 330.6 ± 54.8* 431.0 ± 67.1* 425.9 ± 69.4*
EPO 73.0 ± 40.6 322.8 ± 57.58 337.8 ± 75.7* 236.0 ± 74.78
Volumetric blood flow (pls−1)
ctrl 3.1 ± 1.8 30.3 ± 5.7* 28.7 ± 6.8* 23.0 ± 3.8*
EPO 7.6 ± 4.3 25.4 ± 4.7* 21.5 ± 3.7* 12.5 ± 4.1*
Note. All data are mean ± SEM.
*P < .05, significantly different from Day 3.
#P < .05. significantly different from Day 6.
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F IGURE 3 Effect of EPO-pretreatment on the revascularization of transplanted islets. (A) Intravital microscopic images of islets (marked by
dotted lines) on Days 3 and 6 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were pretreated with vehicle (ctrl-pre)
or EPO (EPO-pre). The plasma marker FITC-dextran was used for the visualization of microvessels in blue light epi-illumination. Scale bar: 50 μm.
(b,c) Functional capillary density (cmcm−2) (b) and revascularized area (mm2) (c) of islets on Days 0, 3, 6, 10, and 14 after transplantation into the
dorsal skinfold chamber of FVB/N mice, which were pretreated with vehicle (ctrl-pre, n = 8) or EPO (EPO-pre, n = 8). Mean ± SEM. #P < .05,
significantly different from Day 0 in each individual group; †P < .05 versus Days 0 and 3 in each individual group; ‡P < .05 versus Days 0, 3, and
6 in each individual group; *P < .05, significantly different from ctrl-pre. (d) Intravital microscopic images of islets as described in (a). Rhodamine
6G was used to visualize endocrine revascularization in green light epi-illumination. Scale bar: 50 μm. (e) Endocrine revascularization of islets on
Days 0, 3, 6, 10, and 14 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were pretreated with vehicle (ctrl-pre n = 8)
or EPO (EPO-pre, n = 8). Mean ± SEM. #P < .05, significantly different from Day 0 in each individual group; †P < .05, significantly different from
Days 0 and 3 in each individual group; *P < .05, significantly different from ctrl-pre. (f,g) Take rate (%) (f) and systemic haematocrit (%) (g) on Day
14 after islet transplantation into the dorsal skinfold chamber of FVB/N mice, which were pretreated with vehicle (ctrl-pre, n = 8) or EPO (EPO-
pre, n = 8). Mean ± SEM. *P < .05, significantly different from ctrl-pre
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transplantation, when the revascularization process was completed in
both groups (Figure 5c,d). The analysis of insulin-, glucagon-, and
somatostatin-positive cells revealed no significant differences
between EPO-pretreated and control grafts on Days 6 and 14 (Fig-
ure 5a–d).
Transplantation of islets from the GFP/Tie2-positive donor mice
into the GFP-negative animals further allowed the analysis of the ori-
gin of the endothelial cells within the grafts (Figure 5e–g). These ana-
lyses showed that the islets in EPO-pretreated mice contained a
significantly lower fraction of GFP/CD31-positive endothelial cells on
Day 6, compared with controls (Figure 5e,g). In contrast, there was no
significant difference in the fraction of GFP/CD31-positive endothe-
lial cells between the two groups on Day 14 (Figure 5f,g).
To assess the effect of EPO-pretreatment on the endocrine func-
tion of the grafts, we performed a suboptimal transplantation of islets
under the kidney capsule of diabetic mice. For this purpose, we first
treated mice with STZ to induce a diabetic phenotype. Six days before
transplantation of 300 islets under the kidney capsule, the animals
were pretreated with EPO or vehicle (Figure 6a). Blood glucose levels
and body weight of the recipient mice were repetitively determined
(Figure 6a). STZ-induced diabetic mice of both groups showed an ini-
tial decrease in body weight due to the STZ treatment (Figure 6b).
However, after transplantation, they recovered and gained body
weight until the end of the experiment (Figure 6b). Analyses of blood
glucose levels revealed a STZ-induced hyperglycaemia, as indicated by
blood glucose levels up to 25 mmolL−1 before transplantation (Fig-
ure 6c). The transplantation of islets resulted in a reduction of blood
glucose levels throughout the observation period of 28 days. Note-
worthy, on Days 7 and 10 after EPO-pretreatment, blood glucose
levels were found significantly more reduced than those in controls.
This led to an accelerated recovery to normoglycaemia (Figure 6c). In
addition, the AUC of blood glucose levels was slightly but not signifi-
cantly reduced in EPO-pretreated mice (Figure 6d). The analyses of
plasma samples after 28 days demonstrated that the insulin levels of
EPO-pretreated animals did not significantly differ from that of con-
trols (Figure 6e). Moreover, after 28 days, the glycoprotein did not
alter the β-cell mass and the number of endothelial cells within the
islet grafts (Figure 6f,g).
4 | DISCUSSION
The aim of the present study was to analyse the effects of EPO on
the revascularization of transplanted pancreatic islets. Our results
demonstrated that EPO accelerated the revascularization of
transplanted islets, resulting in an increased take rate of the grafts and
an improved perfusion of the endocrine tissue. Of interest, this bene-
ficial effect of EPO is especially pronounced if the glycoprotein is
administered prior to islet transplantation.
Insufficient revascularization is thought to be the major cause for
the poor survival of grafted islets during islet transplantation for the
therapy of Type I diabetes (Brissova & Powers, 2008). To overcome
this problem, previous studies suggested the co-transplantation of
stem cells or endothelial cells with islets to enhance the angiogenic
potential of the grafts (Quaranta et al., 2014; Rackham et al., 2011).
However, the application and manipulation of specific cell types is dif-
ficult to realize under clinical conditions not only due to the regulatory
hurdles but also due to time-consuming isolation and cultivation pro-
cedures and difficulties in the standardization of cell quality and islet
yield. Accordingly, the use of pharmacological drugs, which specifically
stimulate angiogenic pathways, may be a more feasible strategy to
improve islet engraftment in clinical practice. Hence, it is necessary to
identify novel pro-angiogenic compounds, which are effective for this
approach without inducing severe side effects.
The haematopoietic cytokine EPO is required for the generation
of RBCs in response to low tissue oxygen levels. EPO binds to its
corresponding receptor on erythroid precursor cells and stimulates
their survival, proliferation, and differentiation via signalling through
kinases such as JAK2, MAPK, and PI3K (Elliott & Sinclair, 2012). Inter-
estingly, studies have demonstrated that beside this effect on erythro-
poiesis, EPO also promotes angiogenesis (Anagnostou, Lee, Kessimian,
Levinson, & Steiner, 1990). For instance, Ribatti et al. (1999) found
TABLE 2 Diameter (μm), centreline RBC velocity (μms−1), and volumetric blood flow (pls−1) of newly formed microvessels within islets on
Days 3, 6, 10, and 14 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were pretreated with vehicle (ctrl-pre, n = 8) or
EPO (EPO-pre, n = 8)
D3 D6 D10 D14
Diameter (μm)
ctrl-pre 11.2 ± 1.6 11.9 ± 0.6 9.0 ± 0.5† 8.8 ± 0.4†
12.0 ± 0.6 9.0 ± 0.3# * 8.2 ± 0.4# 8.7 ± 0.7#
Centreline RBC velocity (μms−1)
ctrl-pre 73.1 ± 31.9 240.5 ± 28.4# 366.4 ± 62.4# 379.2 ± 96.0#
EPO-pre 295.6 ± 72.4* 571.2 ± 75.6# * 671.5 ± 78.2# * 551.8 ± 61.3#
Volumetric blood flow (pls−1)
ctrl-pre 6.6 ± 4.0 18.5 ± 1.7# 18.0 ± 2.9 17.4 ± 3.6
EPO-pre 30.9 ± 8.1* 32.0 ± 5.1* 32.2 ± 7.1 31.7 ± 6.6
Note. All data are mean ± SEM.
#P < .05, significantly different from Day 3. †P < .05, significantly different from Days 3 and 6. *P < .05, significantly different from vehicle.
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that EPO stimulates the formation of new blood vessels in the chick
embryo chorioallantoic membrane. However, this pro-angiogenic
effect seems to depend on the administered dose of EPO. In fact, pre-
vious studies suggest that only low doses (500 IUkg−1) but not high
doses (5000 IUkg−1) of EPO induce angiogenesis (Harder et al.,
2009). Accordingly, we also used a dose of 500 IUkg−1 of EPO, in our
experiments, to stimulate the revascularization of transplanted islets.
In a first set of experiments, we administered EPO daily, starting
from the day of islet transplantation. This treatment protocol resulted
in a higher functional capillary density and slightly increased the endo-
crine revascularization of the grafts compared with controls. However,
the effect of the glycoprotein was only marginal in this experimental
setting. This may be explained by the fact that it takes several days
until VEGF expression is up-regulated in ischaemic tissue in response
to low-dose EPO (Rezaeian et al., 2010). Hence, on Day 3 after
transplantation, the functional capillary density and revascularized
area of islets did not differ between EPO- and vehicle-treated animals.
In contrast, we detected a significantly higher functional capillary den-
sity on Day 6 in EPO-treated mice, while the grafts in both groups
exhibited a comparable vascularization on Day 14. Taken together,
these findings indicate that EPO is capable of accelerating the revas-
cularization process.
To further improve the pro-angiogenic effect of EPO on islet
grafts, we performed a second set of experiments, in which we
pretreated recipient mice with the glycoprotein 6 days prior to islet
transplantation. According to our previous assumptions, we found
that EPO-pretreatment more effectively accelerated the revasculari-
zation process of the grafts. This was shown by a significantly higher
functional capillary density of islets in EPO-pretreated mice between
Days 3 and 10, compared with controls. Moreover, these islets also
F IGURE 4 Effect of EPO on vasodilatation. (a) Observation window of islet-containing dorsal skinfold chambers of vehicle- (ctrl-pre) and
EPO-pretreated (EPO-pre) FVB/N mice on Day 0. Scale bar: 1 mm. (b) Intravital microscopic images of arterioles (a) and venules (v) within dorsal
skinfold chambers of vehicle- (ctrl-pre) and EPO-pretreated (EPO-pre) FVB/N mice on Day 0. The plasma marker FITC-dextran was used for the
visualization of microvessels in blue light epi-illumination. Scale bar: 50 μm. (c,d) Diameter of arterioles (c) and venules (d) on Days 0, 3, 6, 10, and
14 after islet transplantation into the dorsal skinfold chamber of FVB/N mice, which were pretreated with vehicle (ctrl-pre n = 8) or EPO (EPO-
pre, n = 8). Mean ± SEM. #P < .05, significantly different from Day 3 in each individual group; †P < .05, significantly different from Days 0 and 3 in
each individual group; *P < .05, significantly different from ctrl-pre. (e,f) Diameter of arterioles (e) and venules (f) on Days 0, 3, 6, 10, and 14 after
islet transplantation into the dorsal skinfold chamber of FVB/N mice, which were treated with vehicle (ctrl, n = 8) or EPO (n = 8). Mean ± SEM.
bP < .05, significantly different from Days 0 and 3 in each individual group; *P < .05, significantly different from ctrl-pre
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F IGURE 5 Immunohistochemical analysis of transplanted islets. (a) Immunofluorescence staining of insulin/CD31, insulin/glucagon, and
insulin/somatostatin within transplanted islets on Day 6 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were
pretreated with vehicle (ctrl-pre) or EPO (EPO-pre). Scale bar: 50 μm. (b) Insulin-, glucagon-, somatostatin-, and CD31-positive cells (in % of all
islet cells) within transplanted islets on Day 6 after transplantation into the dorsal skinfold chamber of FVB/N mice, which were pretreated with
vehicle (ctrl-pre, n = 3) or EPO (EPO-pre, n = 3). Mean ± SEM. *P < .05, significantly different from ctrl-pre. (c) Immunofluorescence staining of
insulin/CD31, insulin/glucagon, and insulin/somatostatin within transplanted islets on Day 14 after transplantation into the dorsal skinfold
chamber of FVB/N mice, which were pretreated with vehicle (ctrl-pre) or EPO (EPO-pre). Scale bar: 50 μm. (d) Insulin-, glucagon-, somatostatin-,
and CD31-positive cells (in % of all islet cells) within transplanted islets on Day 14 after transplantation into the dorsal skinfold chamber of FVB/
N mice, which were pretreated with vehicle (ctrl-pre, n = 8) or EPO (EPO-pre, n = 8). (e ,f) Immunofluorescence staining of CD31 and GFP within
transplanted islets on Day 6 (e) and Day 14 (f) after transplantation into the dorsal skinfold chamber of FVB/N mice, which were pretreated with
vehicle (ctrl-pre) or EPO (EPO-pre). Arrows = GFP/CD31-positive cells. Scale bar: 50 μm. (g) Number of GFP/CD31-positive cells (in % of all
CD31-positive cells) within transplanted islets on Days 6 and 14 after transplantation into the dorsal skinfold chamber of FVB/N mice, which
were pretreated with vehicle (ctrl-pre, n = 3 (Day 6) and n = 8 (Day 14)) or EPO (EPO-pre, n = 3 (Day 6) and n = 8 (Day 14)). Mean ± SEM. *P < .05,
significantly different from ctrl-pre
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contained a significantly lower fraction of GFP/CD31-positive endo-
thelial cells on Day 6, indicating an increased ingrowth of GFP-nega-
tive endothelial cells from the surrounding host tissue in this initial
phase of islet revascularization. This was associated with a markedly
elevated endocrine revascularization throughout the observation
period and higher number of engrafted islets on Day 14.
The endocrine revascularization of transplanted islets only repre-
sents an indirect marker for their endocrine function. Therefore, we
additionally used the kidney capsule model of diabetic mice (van
Suylichem, Strubbe, Houwing, Wolters, & van Schilfgaarde, 1994) to
confirm an improved endocrine function due to an accelerated revas-
cularization. For this purpose, we transplanted 300 islets under the
kidney capsule of STZ-treated diabetic mice. This represents a sub-
optimal number of islets because they do not restore normoglycaemia
within 10 days (Lai et al., 2005). Of interest, we measured physiologi-
cal blood glucose levels in EPO-pretreated animals already 7 days
F IGURE 6 Effect of EPO-pretreatment on the endocrine function of transplanted islets. (a) Schematic illustration of the experimental setting
of EPO administration and islet transplantation under diabetic conditions. STZ (150 mgkg−1, i.p.) was administered 7 days before islet
transplantation (Tx, Day 0). Mice received daily EPO or vehicle over 6 days. On Day 0, 300 islets were transplanted under the kidney capsule.
Blood glucose levels were measured on Days 7 and 4 before islet transplantation as well as on Days 0, 4, 7, 10, 14, 17, 21, 24, and 28 after islet
transplantation. (b,c) Body weight (b) and blood glucose levels (c) on Days 7 and 4 before transplantation as well as on Days 0, 4, 7, 10, 14, 17,
21, 24, and 28 after islet transplantation in diabetic C57BL/6J mice, which were pretreated with vehicle (ctrl-pre, n = 8) or EPO (EPO-pre, n = 8).
Mean ± SEM. aP < .05, significantly different from Day 0 in each individual group; †P < .05, significantly different from Days 0, 4, 7, 10, and 14 in
each individual group; *P < .05, significantly different from ctrl-pre. (d) AUC of blood glucose levels (a.u., arbitrary units). Mean ± SEM. (e) Plasma
insulin content (μUml−1) of vehicle (ctrl-pre)- and EPO (EPO-pre)-pretreated diabetic C57BL/6 J mice on Day 28 after islet transplantation.
Mean ± SEM. (f) Immunofluorescence stainings of insulin/CD31 within transplanted islets on Day 28 after transplantation under the kidney
capsule of C57BL/6J mice, which were pretreated with vehicle (ctrl-pre) or EPO (EPO-pre). Scale bar: 35 μm. (g) Insulin- and CD31-positive cells
(in % of all islet cells) within transplanted islets on Day 28 after transplantation under the kidney capsule of C57BL/6J mice, which were
pretreated with vehicle (ctrl-pre, n = 5) or EPO (EPO-pre, n = 5). Mean ± SEM
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after islet transplantation. In contrast, normoglycaemia was not
observed in controls until Day 17. On Day 28 after transplantation,
immunohistochemical analyses revealed similar numbers of endothe-
lial cells and beta-cells within the islet grafts of both groups. These
data strengthen our results from the dorsal skinfold chamber model,
showing that EPO-pretreatment accelerated the revascularization of
the grafts without increasing the final overall number of blood vessels.
This can be explained by the fact that angiogenesis depends on the
balance of stimulatory and inhibitory factors (Kota et al., 2012). It is
well known that hypoxia modulates EPO levels by increasing expres-
sion of the EPO gene (Stockmann et al., 2006). EPO, in turn, triggers
angiogenic pathways (Alvarez Arroyo et al., 1998; Li et al., 2007). In
case of the present experimental setting, the exogenous administra-
tion of EPO may already induce these angiogenic pathways within the
grafts on Day 0, independently of hypoxia, resulting in an acceleration
of islet revascularization. However, after the development of a dense
microvascular network, which provides a sufficient oxygen and nutri-
ent supply to the islet cells, anti-angiogenic factors, such as throm-
bospondin-1 (Chen et al., 2000) or IL-1β (Cozzolino et al., 1990), may
contribute to the termination of the angiogenic process. Hence, the
final revascularization of EPO-pretreated and control islets was
comparable.
Interestingly, EPO up-regulates the expression of endothelial NO
synthase, resulting in elevated NO levels (Burger et al., 2006). On the
other hand, Chen, Wang, Asavaritkrai, and Noguchi (2010) reported
that NO stimulates the expression of EPO receptors and, thus, con-
tributes to EPO-mediated protection against hypoxia-induced apopto-
sis. In addition, it is well known that NO is a potent vasodilator. In line
with these findings, we observed a strong vasodilatory effect of EPO
on arterioles and venules of the host tissue. EPO-pretreatment caused
a vasodilatation during the first 6 days, whereas EPO treatment
increased the vessel diameters between Days 6 and 14 after islet
transplantation. Therefore, it may be speculated that several days are
required until the repetitive application of low-dose EPO results in
NO levels sufficient to induce vasodilatation. Of note, it has also been
reported that NO promotes angiogenesis (Ziche & Morbidelli, 2000).
This may have further contributed to our observation that short-term
EPO-pretreatment is more effective in enhancing islet revasculariza-
tion than EPO treatment in the post-transplantation phase.
Several studies demonstrated that EPO is also capable of reduc-
ing pancreatic beta-cell death (Chen et al., 2015; Fenjves et al., 2003;
Fenjves et al., 2004). Watanabe et al. (2016) showed that the
pyroglutamate helix B surface peptide ARA 290, which is highly spe-
cific for EPO receptors and lacks haematopoietic activity, protects
transplanted islets against cytokine-induced apoptosis. Hence, besides
its pro-angiogenic effect, this anti-apoptotic activity of EPO may be
an additional advantage for its application in clinical islet
transplantation.
EPO elevates haemoglobin levels and activates platelets, resulting
in an increased risk of thrombosis (Jelkmann, 1992; Kato et al., 2010;
Stohlawetz et al., 2000). In the present study, the analysis of blood
samples on Day 14 revealed that a daily EPO treatment over 14 days
significantly elevates systemic haematocrit levels when compared to
controls. Importantly, this was not the case when mice were only
pretreated with the glycoprotein for a 6-day period. In fact, these
observations are in line with those of Galeano et al. (2006), demon-
strating that daily EPO administration (400 IUkg−1) over 2 weeks
increases haematocrit levels not earlier than Day 14. Accordingly, the
short-term EPO-pretreatment in the present study did not trigger the
haematopoietic cascade but was capable of inducing angiogenesis.
This is of crucial clinical interest, because islet transplantation is often
associated with portal thrombosis (Kawahara et al., 2011).
In conclusion, we demonstrate that EPO-pretreatment effectively
improved the revascularization of transplanted islets and, thus, accel-
erated restoration of normoglycaemia without increasing systemic
haematocrit levels. These novel findings indicate that EPO-pre-
treatment may represent a promising therapeutic approach to
improve the clinical outcome of islet transplantation.
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